José Everardo Avelino-Cruz

Dr. José Everardo Avelino-Cruz

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
EPE Di Pasquale
E Di Pasquale
FLFrancesco Lodola
Francesco Lodola
MMMichele Miragoli
Michele Miragoli
MDM Denegri
M Denegri
JAJosé Everardo Avelino-Cruz
José Everardo Avelino-Cruz
SPS G Priori
S G Priori
Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system’ that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after β-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca2+/calmodulin-dependent serine–threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies.

22 July 2011 in Circulation Research
Verified
Journal Article
Closed access
PDF file
NLNian Liu
Nian Liu
MDMarco Denegri
Marco Denegri
YRYanfei Ruan
Yanfei Ruan
JAJosé Everardo Avelino-Cruz
José Everardo Avelino-Cruz
APAndrea Perissi
Andrea Perissi
SPSilvia G. Priori
Silvia G. Priori
Rationale:: Flecainide prevents arrhythmias in catecholaminergic polymorphic ventricular tachycardia, but the antiarrhythmic mechanism remains unresolved. It is possible for flecainide to directly affect the cardiac ryanodine receptor (RyR2); however, an extracellular site of action is suggested because of the hydrophilic nature of flecainide. Objective:: To investigate the mechanism for the antiarrhythmic action of flecainide in a RyR2 R4496C+/− knock-in mouse model of catecholaminergic polymorphic ventricular tachycardia. Methods and Results:: Flecainide prevented catecholamine-induced sustained ventricular tachycardia in RyR2 R4496C+/− mice. Cellular studies were performed with isolated RyR2 R4496C+/− myocytes. Isoproterenol caused the appearance of spontaneous Ca 2+ transients, which were unaffected by flecainide (6 μmol/L). Flecainide did not affect Ca 2+ transient amplitude, decay, or sarcoplasmic reticulum Ca 2+ content. Moreover, it did not affect the frequency of spontaneous Ca 2+ sparks in permeabilized myocytes. In contrast, flecainide effectively prevented triggered activity induced by isoproterenol. The threshold for action potential induction was increased significantly ( P <0.01), which suggests a primary extracellular antiarrhythmic effect mediated by Na + channel blockade. Conclusions:: Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in RyR2 R4496C+/− mice; however, at variance with previous reports, we observed minimal effects on intracellular Ca 2+ homeostasis. Our data suggest that the antiarrhythmic activity of the drug is caused by reduction of Na + channel availability and by an increase in the threshold for triggered activity.

24 June 2014 in Circulation
Verified
Journal Article
Open access
MDMarco Denegri
Marco Denegri
RBRossana Bongianino
Rossana Bongianino
FLFrancesco Lodola
Francesco Lodola
SBSimona Boncompagni
Simona Boncompagni
VGVerónica C. De Giusti
Verónica C. De Giusti
SPSilvia G. Priori
Silvia G. Priori
Background—: Catecholaminergic polymorphic ventricular tachycardia is an inherited arrhythmogenic disorder characterized by sudden cardiac death in children. Drug therapy is still insufficient to provide full protection against cardiac arrest, and the use of implantable defibrillators in the pediatric population is limited by side effects. There is therefore a need to explore the curative potential of gene therapy for this disease. We investigated the efficacy and durability of viral gene transfer of the calsequestrin 2 ( CASQ2 ) wild-type gene in a catecholaminergic polymorphic ventricular tachycardia knock-in mouse model carrying the CASQ2 R33Q/R33Q (R33Q) mutation. Methods and Results—: We engineered an adeno-associated viral vector serotype 9 (AAV9) containing cDNA of CASQ2 wild-type (AAV9- CASQ2 ) plus the green fluorescent protein ( GFP ) gene to infect newborn R33Q mice studied by in vivo and in vitro protocols at 6, 9, and 12 months to investigate the ability of the infection to prevent the disease and adult R33Q mice studied after 2 months to assess whether the AAV9- CASQ2 delivery could revert the catecholaminergic polymorphic ventricular tachycardia phenotype. In both protocols, we observed the restoration of physiological expression and interaction of CASQ2, junctin, and triadin; the rescue of electrophysiological and ultrastructural abnormalities in calcium release units present in R33Q mice; and the lack of life-threatening arrhythmias. Conclusions—: Our data demonstrate that viral gene transfer of wild-type CASQ2 into the heart of R33Q mice prevents and reverts severe manifestations of catecholaminergic polymorphic ventricular tachycardia and that this curative effect lasts for 1 year after a single injection of the vector, thus posing the rationale for the design of a clinical trial.

1 December 2010 in Stem Cells and Development
Verified
Journal Article
Closed access
YSYuly Sánchez-Hernández
Yuly Sánchez-Hernández
Umberto LaforenzaUmberto Laforenza
Umberto Laforenza
EBElisa Bonetti
Elisa Bonetti
Jacopo Maria FontanaJacopo Maria Fontana
Jacopo Maria Fontana
SDSilvia Dragoni
Silvia Dragoni
Francesco MocciaFrancesco Moccia
Francesco Moccia
Endothelial progenitor cells (EPCs) may be recruited from the bone marrow to sites of tissue regeneration to sustain neovascularization and reendothelialization after acute vascular injury. This feature makes them particularly suitable for cell-based therapy. In mature endothelium, store-operated Ca2+ entry (SOCE) is activated following emptying of inositol-1,4,5-trisphosphate–sensitive stores, and controls a wide number of functions, including proliferation, nitric oxide synthesis, and vascular permeability. The present work aimed at investigating SOCE expression in EPCs harvested from both peripheral blood (PB-EPCs) and umbilical cord blood (UCB-EPCs) by employing both Ca2+ imaging and molecular biology techniques. SOCE was induced upon either pharmacological (ie, cyclopiazonic acid) or physiological (ie, ATP) depletion of the intracellular Ca2+ pool. Further, store-dependent Ca2+ entry was inhibited by the SOCE inhibitor, N-(4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide (BTP-2). Real-time reverse transcription–polymerase chain reaction and western blot analyses showed that both PB-EPCs and UCB-EPCs express all the molecular candidates to mediate SOCE in differentiated cells, including TRPC1, TRPC4, Orai1, and Stim1. Moreover, pharmacological maneuvers demonstrated that, as well as in differentiated endothelial cells, the signal transduction pathway leading to depletion of the intracellular Ca2+ pool impinged on the phospholipase C/inositol-1,4,5-trisphosphate pathway. Finally, blockage of SOCE with BTP-2 impaired PB-EPC proliferation. These findings provide the first evidence that EPCs express SOCE, which might thus be regarded as a novel target to enhance the regenerative outcome of cell-based therapy.

1 November 2011 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
EPEmanuela Pupo
Emanuela Pupo
APAlessandra Fiorio Pla
Alessandra Fiorio Pla
DADaniele Avanzato
Daniele Avanzato
Francesco MocciaFrancesco Moccia
Francesco Moccia
JAJosé Everardo Avelino-Cruz
José Everardo Avelino-Cruz
Luca MUNARONLuca MUNARON
Luca MUNARON

2 March 2012 in Circulation Research
Verified
Journal Article
Closed access
MDMarco Denegri
Marco Denegri
JAJosé Everardo Avelino-Cruz
José Everardo Avelino-Cruz
SBSimona Boncompagni
Simona Boncompagni
SSStefano Andrea De Simone
Stefano Andrea De Simone
AAAlberto Auricchio
Alberto Auricchio
SPSilvia Giuliana Priori
Silvia Giuliana Priori
Rationale:: Catecholaminergic polymorphic ventricular tachycardia is an inherited disease that predisposes to cardiac arrest and sudden death. The disease is associated with mutations in the genes encoding for the cardiac ryanodine receptor (RyR2) and cardiac calsequestrin (CASQ2). CASQ2 mutations lead to a major loss of CASQ2 monomers, possibly because of enhanced degradation of the mutant protein. The decrease of CASQ2 is associated with a reduction in the levels of Triadin (TrD) and Junctin (JnC), two proteins that form, with CASQ2 and RyR2, a macromolecular complex devoted to control of calcium release from the sarcoplasmic reticulum. Objective:: We intended to evaluate whether viral gene transfer of wild-type CASQ2 may rescue the broad spectrum of abnormalities caused by mutant CASQ2. Methods and Results:: We used an adeno-associated serotype 9 viral vector to express a green fluorescent protein-tagged CASQ2 construct. Twenty weeks after intraperitoneal injection of the vector in neonate CASQ2 KO mice, we observed normalization of the levels of calsequestrin, triadin, and junctin, rescue of electrophysiological and ultrastructural abnormalities caused by CASQ2 ablation, and lack of life-threatening arrhythmias. Conclusions:: We have proven the concept that induction of CASQ2 expression in knockout mice reverts the molecular, structural, and electric abnormalities and prevents life-threatening arrhythmias in CASQ2-defective catecholaminergic polymorphic ventricular tachycardia mice. These data support the view that development of CASQ2 viral gene transfer could have clinical application.